8-K: Elevation Oncology Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements

Elevation Oncology reports its financial results for Q4 and the full year 2024, highlighting progress in its clinical programs, including the Claudin 18.2 ADC (EO-3021) and HER3 ADC (EO-1022).

Summary

• Elevation Oncology announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focused on developing selective cancer therapies, particularly ADCs targeting Claudin 18.2 and HER3.
• Dosing is ongoing in Phase 1 clinical trials evaluating EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/GEJ cancer.
• Initial data from the combination cohorts are expected in 4Q 2025 or 1Q 2026.
• Additional monotherapy data from the dose escalation and expansion cohort of the ongoing Phase 1 clinical trial is expected in 2Q 2025.
• Preclinical data for HER3 ADC EO-1022 will be presented at the AACR Annual Meeting 2025, with plans to file an IND application in 2026.
• As of December 31, 2024, Elevation Oncology had $93.2 million in cash, cash equivalents, and marketable securities, compared to $83.1 million as of December 31, 2023.
• The increase in cash reflects net proceeds of $44.2 million raised through its ATM facility in the first half of 2024, partially offset by cash used to fund operating activities.
• R&D expenses for the fourth quarter of 2024 were $6.6 million, compared to $4.7 million for the fourth quarter of 2023.
• For the year ended December 31, 2024, R&D expenses were $28.6 million, compared to $25.4 million for the year ended December 31, 2023.
• G&A expenses for the fourth quarter of 2024 were $4.0 million, compared to $3.3 million for the fourth quarter of 2023.
• For the year ended December 31, 2024, G&A expenses were $16.1 million, compared to $14.9 million for the year ended December 31, 2023.
• Net loss for the fourth quarter of 2024 was $10.4 million, compared to $7.9 million for the fourth quarter of 2023.
• The company expects its cash, cash equivalents, and marketable securities as of December 31, 2024, will be sufficient to fund its current operations into 2026.

Sentiment

Score: 7

Explanation: The document presents a balanced view with both positive progress in clinical programs and financial stability, offset by increased expenses and net losses. The outlook is cautiously optimistic.

Positives

• Elevation Oncology has a strong cash position of $93.2 million, providing a runway into 2026.
• The company is making progress with its Claudin 18.2 ADC program, EO-3021, with combination trials underway.
• Preclinical data supports the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors, showing statistically superior tumor growth inhibition.
• The HER3 ADC program, EO-1022, is advancing, with preclinical data to be presented at AACR Annual Meeting 2025 and an IND application planned for 2026.
• The company is implementing prospective Claudin 18.2 expression testing to enhance understanding of patient response to EO-3021.

Negatives

• The company reported a net loss of $10.4 million for the fourth quarter of 2024, compared to a net loss of $7.9 million for the fourth quarter of 2023.
• R&D and G&A expenses have increased compared to the previous year.

Risks

• The timing and results of clinical trials are inherently uncertain.
• The company's ability to obtain regulatory approvals for its product candidates is not guaranteed.
• The company's ability to fund development activities and achieve development goals is subject to risks and uncertainties.
• The company faces risks related to protecting its intellectual property and establishing and maintaining collaborations with third parties.

Future Outlook

Elevation Oncology expects its cash, cash equivalents, and marketable securities as of December 31, 2024, will be sufficient to fund its current operations into 2026.

Management Comments

• Joseph Ferra, President and Chief Executive Officer of Elevation Oncology, stated that the company continues to advance its Claudin 18.2 ADC program, EO-3021, for the treatment of advanced gastric/GEJ cancer.
• Mr. Ferra believes EO-3021 has the potential to benefit a broad patient population based on its competitive anti-tumor activity and differentiated safety profile.
• Mr. Ferra mentioned that the company introduced prospective Claudin 18.2 testing to the monotherapy dose expansion cohort of its ongoing Phase 1 trial to enhance understanding of patient response.
• Mr. Ferra stated that the company continues to develop its HER3 ADC EO-1022 for the treatment of a wide range of HER3-expressing solid tumors.

Industry Context

Elevation Oncology is operating in the competitive oncology space, focusing on ADC therapies, which are gaining traction as targeted cancer treatments. The company's focus on Claudin 18.2 and HER3 targets aligns with industry trends in developing therapies for solid tumors with significant unmet medical needs.

Comparison to Industry Standards

• Elevation Oncology's focus on ADC development aligns with companies like Seagen, Immunomedics (acquired by Gilead), and ADC Therapeutics, which are leaders in the ADC space.
• The company's Claudin 18.2 program targets a similar pathway as Astellas' zolbetuximab, which is also being developed for gastric cancer.
• The cash runway into 2026 provides Elevation Oncology with financial stability comparable to other similarly sized biotech companies in the clinical development stage.
• The preclinical data showing superior tumor growth inhibition with EO-3021 in combination with VEGFR2 or PD-1 inhibitors is promising and could position the company competitively in the gastric/GEJ cancer treatment landscape.

Stakeholder Impact

• Shareholders: The financial results and clinical progress provide information for investment decisions.
• Employees: The company's financial stability and pipeline progress support job security and growth opportunities.
• Patients: The development of new cancer therapies offers potential treatment options for unmet medical needs.
• Partners: The company's progress in clinical trials and preclinical development strengthens its collaborations with third parties.

Next Steps

• Report additional safety and efficacy data from the ongoing Phase 1 clinical trial of monotherapy EO-3021 in the second quarter of 2025.
• Report initial data from the combination cohorts of the Phase 1 clinical trial of EO-3021 in the fourth quarter of 2025 or the first quarter of 2026.
• Present preclinical data for EO-1022 at the AACR Annual Meeting in the second quarter of 2025.
• File an IND application for EO-1022 in 2026.

Key Dates